Status:
ACTIVE_NOT_RECRUITING
Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborating Sponsors:
Vanderbilt University
Bristol-Myers Squibb
Conditions:
Metastatic Solid Tumor
SF3B1 Gene Mutation
Eligibility:
All Genders
18+ years
Brief Summary
This study is being done to see if patients with metastatic solid tumors (hematologic malignancies and lymphoma excluded) who have a specific genetic mutation in patients' tumor (the SF3B1, U2AF1 or S...
Detailed Description
This is a non-therapeutic study, meaning that while Johns Hopkins is providing a treatment recommendation based on participants' genetic information, participants and participants' oncologist will dec...
Eligibility Criteria
Inclusion
- Performance status eligible for immune checkpoint blockade as determined by local physician
- Able to demonstrate histologically proven locally advanced or metastatic solid tumors (hematologic malignancies and lymphoma excluded)
- genomic testing demonstrating a spliceosome mutation (SF3B1, U2AF1 or SRSF2)
Exclusion
- Local physician determines has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
- Local physician determines the patient has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate
Key Trial Info
Start Date :
September 17 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2026
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT04447651
Start Date
September 17 2020
End Date
August 1 2026
Last Update
July 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins University
Baltimore, Maryland, United States, 21236